| SiDMAP, LLC 2990 S. Sepulveda Blvd. #300B, Los Angeles, CA 90064 |
SiDMAP – Metabolomics for Drug Development
News
- SiDMAP’s scientific advisor delivers talk showing single [1,2-13C2]-D-Glucose tracer cross-labels intracellular stearic acid and better traces mechanistic rosiglitazone response than what was obtained with extracellular [U-13C18]-stearate incubation in a separate study using HepG2 cells.
- Targeted tracer fate association study finds links among metformin, cholesterol, K-ras and pancreatic cancer growth-control
- Combined genomics and targeted tracer fate association approach utilized in characterizing stress response in cancer
- SiDMAP Collaboration with University of Utah School of Medicine Published in FASEB Journal
- SiDMAP Collaboration With National Cancer Institute To Be Presented at The 2013 World Biotechnology Conference
- Global Metabolomics Market to Reach $863.8 Million by 2017, According to a New Report by Global Industry Analysts, Inc.
- SiDMAP studies of two Amgen anti-diabetic agents demonstrate mechanisms of glucose homeostatis regulation and energy metabolism.